Updated:
Hemab Therapeutics
Hemab Therapeutics develops bispecific antibodies for rare bleeding disorders. Its lead candidate HMB-001 targets Glanzmann thrombasthenia.
Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company developing bispecific antibody therapies for underserved bleeding and clotting disorders. The company's name derives from 'hemostasis,' reflecting its core focus on restoring hemostatic balance in patients with conditions such as Glanzmann thrombasthenia and other rare coagulopathies. Its lead programs aim to address the prophylactic and on-demand treatment gaps left by current standards of care. Hemab's platform centers on antibody engineering designed to mimic or restore the function of missing or dysfunctional coagulation factors. Its lead candidate, HMB-001, targets Glanzmann thrombasthenia, a rare inherited bleeding disorder with no approved prophylactic therapy. The company has also disclosed earlier-stage work on additional bispecific antibodies for broader hemostatic indications. Hemab operates primarily through internal discovery and preclinical development, advancing assets toward clinical proof-of-concept. The company has secured backing from a syndicate of life-science focused investors including Novo Holdings, RA Capital Management, and HealthCap. A Series B financing round, co-led by Deep Track Capital and Avoro Capital Advisors, expanded the syndicate and provided capital to advance HMB-001 through early clinical trials. Hemab maintains operations in both Cambridge, Massachusetts, and Copenhagen, Denmark — a transatlantic structure that reflects its origins and investor base. Hemab's structural distinction lies in its single-minded focus on bispecific antibodies for disorders of hemostasis — a rare strategy in a field dominated by factor-replacement and gene-therapy approaches. The company's dual presence in the US and Europe gives it access to distinct regulatory pathways and talent pools, a pragmatic hedge for a platform targeting ultra-rare indications with small patient populations and high regulatory complexity.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Hemab Therapeutics' lead clinical program?
Hemab's lead candidate is HMB-001, a bispecific antibody in development for the treatment of Glanzmann thrombasthenia, a rare inherited bleeding disorder. The program entered Phase 1/2 clinical testing in early 2024, with dosing initiated in January of that year (per the company, January 2024). The drug is designed to provide prophylactic bleeding control for a patient population that currently lacks an approved preventive therapy.
Who are the major investors in Hemab Therapeutics?
Hemab's investor syndicate includes life-science specialists Novo Holdings, RA Capital Management, and HealthCap. The company raised a Series B round co-led by Deep Track Capital and Avoro Capital Advisors, which brought additional crossover investors into the capitalization table. This syndicate reflects a dual US-European investor base aligned with the company's operations in Cambridge, Massachusetts and Copenhagen, Denmark.
How does Hemab's bispecific antibody approach differ from gene therapy for bleeding disorders?
Gene therapy for hemophilia seeks to deliver a functional copy of a missing clotting factor gene, while Hemab's bispecific antibodies are engineered proteins that mimic the bridging function of coagulation factors. Bispecifics offer a reversible, dose-adjustable treatment modality without permanently altering a patient's genome. For ultra-rare disorders like Glanzmann thrombasthenia, where the genetic target is more complex, antibody-based approaches may present a nearer-term therapeutic option.
Why does Hemab maintain operations in both Copenhagen and Cambridge?
The dual-Atlantic structure traces to the company's founding and early venture backing from Nordic investors, combined with the concentration of US-based life-science talent and clinical-trial infrastructure in the Boston area. Having a presence in both regions facilitates parallel regulatory engagement with the EMA and FDA, which is valuable for an ultra-orphan indication where clinical-trial enrollment must span multiple countries to reach statistical targets.
What is the current treatment landscape for Glanzmann thrombasthenia?
Glanzmann thrombasthenia is an inherited platelet disorder caused by a deficiency of the glycoprotein IIb/IIIa receptor. Current management relies on platelet transfusions for major bleeding episodes and off-label use of antifibrinolytics and recombinant factor VIIa. There is no approved prophylactic therapy, meaning patients live with spontaneous bleeding risk and must seek emergency care for each bleeding event — the gap Hemab's HMB-001 aims to fill.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: